A Search Service for Abbreviation / Long Form

■ Abbreviation / Long Form : IFA / ifosfamide

[Related PubMed/MEDLINE]
Total Number of Papers: 18
[Entries Per Page]
 per page
Page Control
Page: of
Abbreviation:   IFA  (>> Co-occurring Abbreviation)
Long Form:   ifosfamide
 Abbreviation Variation
 Long Form Variation
 Pair(Abbreviation/Long Form) Variation
No. Year Title Co-occurring Abbreviation
2019 Hypoxia increases chemoresistance in human medulloblastoma DAOY cells via hypoxia‑inducible factor 1alpha‑mediated downregulation of the CYP2B6, CYP3A4 and CYP3A5 enzymes and inhibition of cell proliferation. CPA
2018 Possible role of CYP2B6 genetic polymorphisms in ifosfamide-induced encephalopathy: report of three cases. IIE
2015 Activation of the anticancer drugs cyclophosphamide and ifosfamide by cytochrome P450 BM3 mutants. CPA, GDEPT
2011 Ifosfamide induced Fanconi syndrome. ---
2009 Preclinical activity of palifosfamide lysine (ZIO-201) in pediatric sarcomas including oxazaphosphorine-resistant osteosarcoma. CPA, ES, MTD, OS, RMS
2008 Mouse mammary tumor virus promoter-containing retroviral promoter conversion vectors for gene-directed enzyme prodrug therapy are functional in vitro and in vivo. CPA, CYP2B1, GDEPT, MMTV, ProCon
2006 Enantiomer-enantiomer interaction of ifosfamide in the rat. AUC, CLR, GC/MS, HOIF, IPM, MRT, N2D, N3D, Vss
2006 Stereoselectivity in metabolism of ifosfamide by CYP3A4 and CYP2B6. HOIF, N2D, N3D
2005 Enantioselective metabolism and cytotoxicity of R-ifosfamide and S-ifosfamide by tumor cell-expressed cytochromes P450. CPA
10  2004 Activation of the anticancer prodrugs cyclophosphamide and ifosfamide: identification of cytochrome P450 2B enzymes and site-specific mutants with improved enzyme kinetics. CPA
11  2002 Cytochrome P450-based cancer gene therapy: current status. CPA, GDEPT
12  2002 Regioselectivity of CYP2B6: homology modeling, molecular dynamics simulation, docking. CPA, MD
13  2000 Role of human liver microsomal CYP3A4 and CYP2B6 in catalyzing N-dechloroethylation of cyclophosphamide and ifosfamide. CPA
14  1999 Development of a substrate-activity based approach to identify the major human liver P-450 catalysts of cyclophosphamide and ifosfamide activation based on cDNA-expressed activities and liver microsomal P-450 profiles. CPA, CYP, RSF
15  1999 High-performance liquid chromatographic-fluorescent method to determine chloroacetaldehyde, a neurotoxic metabolite of the anticancer drug ifosfamide, in plasma and in liver microsomal incubations. CA
16  1999 Stereoselective metabolism of ifosfamide by human P-450s 3A4 and 2B6. Favorable metabolic properties of R-enantiomer. CYP, DCl
17  1998 Retroviral transfer of human cytochrome P450 genes for oxazaphosphorine-based cancer gene therapy. CPA
18  1996 Sensitization of human breast cancer cells to cyclophosphamide and ifosfamide by transfer of a liver cytochrome P450 gene. CMV, CPA